Quantitative 68Ga-PSMA-11 PET and Outcomes in Metastatic Castration-resistant Prostate Cancer following 177Lu-PSMA-617
Radiology Podcasts | RSNA - En podcast av The Radiological Society of North America - Tisdagar
Dr. Ashwin Singh Parihar speaks with Dr. Phillip Kuo, Dr. Andrew Armstrong, and Dr. Ken Herrmann about how 68Ga-PSMA-11 PET can predict response of metastatic prostate cancer following 177Lu-PSMA-617 therapy. The VISION Trial. Quantitative 68Ga-PSMA-11 PET and ClinicalOutcomes in Metastatic Castration-resistant ProstateCancer Following 177Lu-PSMA-617 (VISION Trial). Kuo and Morris et al. Radiology 2024; 312(2):e233460.
